Use of the pentapeptide PHSRN in ophthalmic formulations

摘要

An object is to find the minimum activity expression site of fibronectin, clarify the actions of this minimum unit in relation to ophthalmological fields, and provide a ophthalmological composition having this minimum unit as an effective component. This invention provides an ophthalmological composition, in particular, a corneal disorder treatment agent containing the peptide, PHSRN (Pro-His-Ser-Arg-Asn), or Ac-Pro-His-Ser-Arg-Asn-NH2, which is a derivative thereof, or a salt thereof that is allowable as a medical drug as an effective component. The preferred dosage form is an ophthalmic formulation.